It will provide a theoretical basis for whether irAEs can be considered as a clinical marker for predicting the efficacy of PD-1 inhibitors combination therapy, and provide evidence for the precise screening of CCA patients who may benefit from PD-1 inhibitors combination therapy. The gene discussed is PDCD1; the disease is cholangiocarcinoma.